Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MasterKey-01: A Phase 1/2, Open-label, Two-part, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics & Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB Mutations, in Patients w/ Advanced Solid Malignancies

NCT04209465 is registered in ClinicalTrials.gov with Black Diamond Therapeutics, Inc. as lead sponsor.

NCT NCT04209465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04209465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MasterKey-01: A Phase 1/2, Open-label, Two-part, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics & Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB Mutations, in Patients w/ Advanced Solid Malignancies
Lead sponsor
Black Diamond Therapeutics, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
December 19, 2019
Completion date
September 16, 2022
Enrollment
91 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor